INTRODUCTION
============

Duloxetine, a serotonin noradrenaline reuptake inhibitor (SNRI), is an effective first-line treatment for patients with major depressive disorder (MDD). Recently, duloxetine has also been considered useful for diabetic painful neuropathy and fibromyalgia.[@B1] Generally, duloxetine is safe and well tolerated, although nausea, headache, dry mouth, insomnia, general fatigue, constipation, diarrhea, dizziness, sweating, sexual dysfunction, and appetite loss have been reported in patients with MDD.[@B1] Previously, we reported that milnacipran, another SNRI, increased the plasma levels of 3-methoxy-4-hydroxyphenylglycol (MHPG), a major metabolite of noradrenalin, in patients with MDD.[@B2] Duloxetine potently inhibits both serotonin and noradrenaline transporters. Therefore, we hypothesized that duloxetine also increases plasma MHPG levels in patients with MDD.

Brain-derived neurotrophic factor (BDNF) plays an important role in the pathogenesis of MDD. We also demonstrated that milnacipran significantly increased serum BDNF levels in patients with MDD compared with healthy subjects.[@B2],[@B3] However, three meta-analyses of studies of blood BDNF levels demonstrated that the serum or plasma BDNF in patients with MDD are lower than are those in healthy contols.[@B4],[@B5],[@B6] These findings imply that blood BDNF level is a biomarker for MDD. We hypothesized that duloxetine increases serum BDNF levels.

To confirm this hypothesis, this study investigated the effects of duloxetine on the plasma catecholamine metabolite and serum BDNF levels in depressed patients. To our knowledge, this is the first such study.

METHODS
=======

Subjects
--------

Sixty-four patients were recruited. Major depressive episode was diagnosed using the structured clinical interview for the Diagnostic and Statistical Manual of Mental Disorders-fourth edition (DSM-IV) according to DSM-IV text revision (DSM-IV-TR) criteria. The severity of depression was evaluated using the 17-item Hamilton Rating Scale for Depression (HAMD-17). In terms of the somatic symptoms of depression, we included items \#10 (anxiety-psychic), \#11 (anxiety-somatic), \#12 (somatic symptoms-gastrointestinal), \#13 (somatic symptoms-general), and \#15 (hypochondriasis) of the HAMD-17. Exclusion criteria were a history of neurological or other physical diseases; comorbidity with other disorders, bipolar disorder, or Axis II personality disorders and mental retardation. No patient received antidepressants or benzodiazepines for at least 1 week before starting the study. We defined patients whose HAMD-17 scores decreased by 50% or more as responders. Demographic data for duloxetine responders and non-responders are shown in [Table 1](#T1){ref-type="table"}. Blood sampling and clinical evaluations were performed on days 0, 28 (4 weeks), and 56 (8 weeks). Of the 64 patients, 45 patients (70%) finished the study. The reasons for dropping out are presented in [Table 2](#T2){ref-type="table"}. Written informed consent was obtained via forms approved by the ethics committee of the University of Occupational and Environmental Health (230737).

Methods
-------

### Plasma catecholamine metabolites and serum BDNF assays

The plasma homovanillic acid (HVA) and MHPG concentrations were analyzed using high-performance liquid chromatography with electrochemical detection (HPLC-ECD) according to our reported method,[@B7] and serum BDNF was measured using a BDNF Emax Immunoassay kit (Promega, Madison, WI, USA) according to the manufacturer\'s instructions.

### Statical analyses

The Bonferroni method for a repeated-measures analysis of variance (ANOVA) was used for *post hoc* analysis of comparisons among three groups. Pearson\'s correlation coefficient was used to compare pairs of groups. The level of significance for all analyses was set at *p*\<0.05.

RESULTS
=======

Thirty of the 45 (67%) patients responded to 8 weeks of duloxetine treatment. Duloxetine treatment for 8 weeks significantly increased the plasma MHPG levels (*p*=0.0062) in responders but did not change the plasma MHPG levels in non-responders ([Fig. 1](#F1){ref-type="fig"}). Duloxetine did not change the plasma HVA levels in either responders (*p*=1.000) or non-responders (*p*=0.2974) ([Fig. 2](#F2){ref-type="fig"}). No significant correlation was observed between changes in the total HAMD-17 scores and changes in plasma MHPG or HVA levels. Additionally, no correlation was found between changes in plasma MHPG or HVA levels and those in the subitem scores on the HAMD-17.

Duloxetine treatment for 8 weeks did not significantly increase serum BDNF levels in either responders (*p*=0.8055) or non-responders (*p*=1.000). We also analyzed the relationship between the somatic symptoms of depression and the plasma catecholamine metabolite levels in duloxetine responders. No significant positive correlations were found between scores on the somatic symptom scores addressed by the HAMD-17 and baseline levels of plasma MHPG (*r*=0.021, *p*=0.7130) or HVA (*r*=0.1661, *p*=0.2754). An increase in BDNF was not also observed even in responders to duloxetine (*p*=0.3073) ([Fig. 3](#F3){ref-type="fig"}).

DISCUSSION
==========

This is the first report that duloxetine increases plasma MHPG levels in MDD responders. The increase plasma MHPG levels is consistent with the fact that duloxetine effectively inhibits the noradrenaline transporter (NAT). As MDD is a heterogeneous disorder, the levels of plasma MHPG and HVA vary widely in patients[@B2] and are higher in depressed patients than in normal controls; on the other hand, they were lower in depressed patients than in normal controls. Therefore, it is possible that duloxetine acts on noradrenergic neurons in patients with MDD. Noradrenaline is associated primarily with attention, activity, concentration, and pain. Duloxetine might alter the symptoms of MDD by enhancing noradrenaline neurons. Nevertheless, no correlation was observed between changes in plasma MHPG levels and changes in the subitem scores on the HAMD-17. Furthermore, duloxetine did not change plasma HVA levels in the patient group. As there are few dopamine transporters (DATs) in the prefrontal cortex, dopamine reuptake occurs through the NAT. Therefore, it is plausible that treatment with duloxetine for 8 weeks increases plasma HVA. The fact that duloxetine does not directly inhibit DATs might be the reason for the lack of an observed increase in plasma HVA levels. By contrast, Chalon et al.[@B8] reported that 5-6 days of duloxetine significantly decreased urinary MHPG levels in healthy volunteers. The discrepancy between the studies could be due to differences in sampling methods or study periods. Indeed, the plasma MHPG levels of patients with MDD who responded to milnacipran were significantly lower than were those of healthy subjects.[@B2]

Another important finding of our study was that duloxetine treatment for 8 weeks did not increase serum BDNF levels in responders or non-responders with MDD. All of the subjects in our previous milnacipran study were drug-naïve. By contrast, most of the current patients had been given several antidepressants before staring duloxetine. Although we stopped these drugs for 1 week, this period might have been too short to rule out the effects of the other antidepressants on serum BDNF. Therefore, it is possible that serum BDNF levels were influenced by medications that were received before duloxetine was started.

There are several limitations to this study. First, it was an open-label trial rather than a double-blind, fixed-dose study. Second, the sample size was small, and the drop-out rate was high. Third, there was no healthy control group, and the follow-up period was short. Fourth, plasma MHPG and HVA levels are thought to reflect only 30-50% and 10-20% of the dynamics of the brain, respectively.[@B3] Finally, the lack of data on the drop-outs might have had an enormous influence on the results. As most of those patients could be considered non-responders, our results might have been more robust than if they had been included. Further research considering these problems should be performed to confirm our preliminary results. In conclusion, treatment with duloxetine for 8 weeks increased plasma MHPG levels in responders but not nonresponders with MDD, which suggests that enhancing noradrenaline neurons plays an important role in alleviating depressive symptoms.
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###### 

Demographic data of responder and nonresponder to duloxetine
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Values are presented as number only or mean±standard deviation. M, male; F, female; HAMD-17, the 17-item Hamilton Rating Scale for Depression.

###### 

The reason for drop out
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